Difference between revisions of "Boehringer-Ingelheim"
(removed logo) |
Josh Leeson (talk | contribs) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | Boehringer-Ingelheim was founded in Ingelheim, Germany, in 1885. The company under Albert Boehringer established a reputation for social enlightenment and tehnologically innovative products | + | '''Boehringer-Ingelheim''' was founded in Ingelheim, Germany, in 1885. The company under [[Albert Boehringer]] established a reputation for social enlightenment and tehnologically innovative products.<ref>: http://www.boehringer-ingelheim.com/corporate/corp/corp_hist1_1.htm (Boehringer-Ingelheim history)</ref> |
Boehringer introduced benefits to his workforce deemed 'remarkably enlightened and generous for the time', including a health insurance scheme in 1902, annual holiday entitlement employee travel subsidiaries in 1910, and a company pension in 1912.<ref>http://www.boehringer-ingelheim.com/corporate/corp/corp_hist1_1_3.htm (Boehringer-Ingelheim, Social Welfare Pioneer),</ref> | Boehringer introduced benefits to his workforce deemed 'remarkably enlightened and generous for the time', including a health insurance scheme in 1902, annual holiday entitlement employee travel subsidiaries in 1910, and a company pension in 1912.<ref>http://www.boehringer-ingelheim.com/corporate/corp/corp_hist1_1_3.htm (Boehringer-Ingelheim, Social Welfare Pioneer),</ref> | ||
Boehringer-Ingelheim Pharmaceuticals focuses largely on human pharmaceuticals (prescription medicines, consumer health care and biopharmaceuticals. Specific areas of interest are: acute coronary disease, arthritis, COPD, HIV/AIDS, Hypertension, Parkinson’s Disease, Restless Legs Syndrome, Stoke and Thromboembolic Diseases. Wellknown products include Antistax, Buscopan and Dulcolax.<ref>http://www.boehringer-ingelheim.com/corporate/products/index.asp (Boehringer-Ingelheim products)</ref> | Boehringer-Ingelheim Pharmaceuticals focuses largely on human pharmaceuticals (prescription medicines, consumer health care and biopharmaceuticals. Specific areas of interest are: acute coronary disease, arthritis, COPD, HIV/AIDS, Hypertension, Parkinson’s Disease, Restless Legs Syndrome, Stoke and Thromboembolic Diseases. Wellknown products include Antistax, Buscopan and Dulcolax.<ref>http://www.boehringer-ingelheim.com/corporate/products/index.asp (Boehringer-Ingelheim products)</ref> | ||
| − | Boehringher Ingelheim took $10. | + | Boehringher Ingelheim took $10.84bn in global sales and spent $1,14bn on research and design in 2005.<ref>Gray, N. (2006) Changing Landscapes: A special Report on the World’s Top 50 Pharma Companies, Pharmaceutical Executive. Available online at: pharmexec.findpharma.com/pharmexec/2005-Pharm-Exec-50-revised/ArticleStandard/Article/detail/354138 </ref> |
==Lobbying and PR firms== | ==Lobbying and PR firms== | ||
*[[Chambre Public Affairs]] | *[[Chambre Public Affairs]] | ||
| + | *[[Pagefield]]<ref> [http://www.appc.org.uk/members/register/register-profile/?company=Pagefield Register 1st September 2014 - 30th November 2014] ''APPC'', accessed 28 January 2015 </ref> | ||
==Notes== | ==Notes== | ||
<references/> | <references/> | ||
Latest revision as of 15:31, 28 January 2015
Boehringer-Ingelheim was founded in Ingelheim, Germany, in 1885. The company under Albert Boehringer established a reputation for social enlightenment and tehnologically innovative products.[1] Boehringer introduced benefits to his workforce deemed 'remarkably enlightened and generous for the time', including a health insurance scheme in 1902, annual holiday entitlement employee travel subsidiaries in 1910, and a company pension in 1912.[2]
Boehringer-Ingelheim Pharmaceuticals focuses largely on human pharmaceuticals (prescription medicines, consumer health care and biopharmaceuticals. Specific areas of interest are: acute coronary disease, arthritis, COPD, HIV/AIDS, Hypertension, Parkinson’s Disease, Restless Legs Syndrome, Stoke and Thromboembolic Diseases. Wellknown products include Antistax, Buscopan and Dulcolax.[3]
Boehringher Ingelheim took $10.84bn in global sales and spent $1,14bn on research and design in 2005.[4]
Lobbying and PR firms
Notes
- ↑ : http://www.boehringer-ingelheim.com/corporate/corp/corp_hist1_1.htm (Boehringer-Ingelheim history)
- ↑ http://www.boehringer-ingelheim.com/corporate/corp/corp_hist1_1_3.htm (Boehringer-Ingelheim, Social Welfare Pioneer),
- ↑ http://www.boehringer-ingelheim.com/corporate/products/index.asp (Boehringer-Ingelheim products)
- ↑ Gray, N. (2006) Changing Landscapes: A special Report on the World’s Top 50 Pharma Companies, Pharmaceutical Executive. Available online at: pharmexec.findpharma.com/pharmexec/2005-Pharm-Exec-50-revised/ArticleStandard/Article/detail/354138
- ↑ Register 1st September 2014 - 30th November 2014 APPC, accessed 28 January 2015
